Key Clinical Summary: ARIA Detection, Escalation, and System Readiness

This micro-learning module is a summary of the presentations by Dr. Tammie L. S. Benzinger, Dr. Petrice M. Cogswell and Dr. Ana M. Franceschi, which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

1. Molecular Neuroimaging in Early Alzheimer's Disease Diagnosis

Clinical practice has shifted from a purely phenotypic or clinical diagnosis to a biological, biomarker-based diagnosis of Alzheimer's disease (AD) and related neurocognitive disorders. Utilizing multiple positron emission tomography (PET) modalities allows for precise patient selection and monitoring within evidence-based pathways.

Amyloid PET

Clinical Value: Confirms parenchymal beta-amyloid plaque burden and serves as the primary screening tool to triage patients for anti-amyloid disease-modifying therapies.
Interpretation Pathway: Diagnostic interpretation relies primarily on visual read assessment (identifying loss of the gray-white matter junction), adjuncted by Centiloid scale quantification.
Key Centiloid Thresholds:
- Centiloid less than 10: generally corresponds with a visually negative study, indicating an absence of amyloid plaques.
- Centiloid greater than 30: generally corresponds with a positive study and established beta-amyloid plaque pathology.
- Clinical Trial Context: Typical mean values for treated cohorts range between 75 and 95 Centiloids. Discrepancies between visual reads and quantitative scores must be detailed in the radiology report with an explicit rationale.

Tau PET

Clinical Value: Identifies tau neurofibrillary tangles, which occur later in the disease cascade, spread in a predictable stepwise pattern, and drive active neurodegeneration.
Prognostic Impact: Used for differential diagnosis, biological disease staging and predicting treatment response. Patients presenting with a high or advanced neocortical tau burden are expected to derive less benefit from amyloid-targeting therapies compared to those with low-to-medium tau accumulation.

FDG PET

Clinical Value: Maps regional glucose metabolism to assist in the differential diagnosis of neurodegenerative diseases.
Application: Critically useful for evaluating patients with suspected mixed dementias in the setting of co-pathology or atypical presentations, such as distinguishing AD subtypes (e.g., left-sided temporal and parietal hypometabolism in logopenic primary progressive aphasia) from frontotemporal lobar degeneration (FTLD).

2. Recognizing, Diagnosing, and Managing ARIA

Amyloid-Related Imaging Abnormalities (ARIA) are known complications of anti-amyloid monoclonal antibody immunotherapies. They stem from a loss of vascular integrity and blood-brain barrier breakdown as amyloid is cleared from the brain parenchyma and shifted into vessel walls.

ARIA Subtypes

ARIA-E (Edema): Represents interstitial vasogenic edema and/or sulcal effusions.
ARIA-H (Hemorrhage): Represents microhemorrhages (microbleeds) and superficial siderosis.

Standardized Neuroradiology Protocol

Safety monitoring requires structured serial brain MRIs, ideally performed on the same scanner type, systematically evaluated against a pre-treatment baseline scan obtained within 3 to 6 months prior to initiating therapy. Essential sequences include:

T2 FLAIR: Optimized for identifying parenchymal hyperintensities and sulcal effusions characteristic of ARIA-E.
T2 Gradient-Recalled Echo (GRE) and/or Susceptibility-Weighted Imaging (SWI): Mandatory sequences for evaluating ARIA-H. Utilizing both maximizes detection sensitivity while helping differentiate microhemorrhages and superficial siderosis from confounding vessel structures.
Diffusion-Weighted Imaging (DWI): Utilized to definitively differentiate ARIA findings from cytotoxic ischemia.

Imaging-Based Severity Grading

ARIA is graded entirely on radiological findings, completely independent of the patient's clinical symptom status, as discussed in the video.

Clinical Management Protocols

Mild or Asymptomatic ARIA: Often managed by temporarily suspending the therapeutic infusions based on specific appropriate use recommendations (AURs) and FDA label guidelines.
Moderate-Severe or Symptomatic ARIA: Requires immediate suspension of therapy. Management may necessitate hospitalization, intensive clinical monitoring, and treatment with high-dose glucocorticoids (steroids) followed by a gradual taper.

AI Integration and Diagnostic Pitfalls

Artificial intelligence (AI) detection software functions as a highly sensitive clinical adjunct to identify subtle abnormalities like microbleeds or highly localized ARIA-E hugging the cortical ribbon. However, it features moderate specificity and can generate false positives.

Artifact Confusion: Radiologists must carefully distinguish real ARIA-E from imaging artifacts, such as dural sinus flow aliasing that can mimic cerebellar or brainstem edema on abbreviated protocol sequences.
Detection Failures: Key pitfalls include overlooking subtle sulcal effusions on FLAIR, missing thin bands of superficial siderosis near the skull base or vertex on GRE/SWI, and failing to meticulously perform serial microbleed counts relative to baseline exams.

3. Emergency Department Management & Multidisciplinary Escalation

Symptomatic ARIA may present as a stroke mimic. Patients may present to the emergency department (ED) with acute neurological deficits—such as sudden changes in speech, altered gait, or severe headaches—that activate automated stroke code protocols.

The Core Risk: Thrombolysis-Induced Hemorrhage

Active anti-amyloid therapy constitutes a relative contraindication to intravenous thrombolytic agents such as tissue plasminogen activator (tPA/alteplase). Administering thrombolytics to a patient with active ARIA or advanced cerebral amyloid angiopathy (CAA) disrupts fragile vascular structures, carrying an exceptionally high risk of inducing catastrophic, potentially fatal intracranial hemorrhage.

CT Red Flags for CAA and ARIA

Because patients are frequently scanned via rapid-access head CT prior to full registration or chart review, the reading radiologist represents a vital line of defense against inappropriate treatment. Surveillance must be actively maintained for the following subtle CT markers:

Convexity Subarachnoid Hemorrhage (SAH): Subtle, localized hyperdensity tracking within the sulci over the cerebral convexities (not within the basal cisterns).
Prior Lobar Hemorrhage: Evidence of older, non-hypertensive intraparenchymal bleeding with characteristic finger-like projections or superficial extension.
Asymmetric White Matter Hyperdensities: Extensive low-attenuation tracking outside of expected vascular territorial boundaries, signaling possible underlying vasogenic edema or severe CAA-related inflammation.
Absence of Large Vessel Occlusion: Acute focal deficits in the absence of an early ischemic core or a corresponding CTA vessel cutoff should immediately prompt consideration of a stroke mimic like ARIA.

Closed-Loop Escalation Strategy

If a CT red flag is identified, or if a patient's history reveals active treatment with anti-amyloid monoclonals (such as lecanemab or donanemab), the radiologist must implement immediate closed-loop verbal communication:

Withhold Thrombolysis: Telephone the emergency medicine and stroke teams immediately to pause the administration of tPA.
Order Urgent Brain MRI: Direct the patient stat to an MRI tracking pathway.
Execute DWI Differentiation: Utilize Diffusion-Weighted Imaging as the definitive differentiator. True acute ischemic stroke demonstrates restricted water diffusion (cytotoxic edema, dark on ADC), whereas ARIA-E reveals free water movement (vasogenic edema, bright on T2/FLAIR without corresponding restricted diffusion on DWI).

4. Integrating Risk and Workflow Guidelines

Optimizing safety across clinical workflows requires institutional preparedness, adherence to standardized monitoring guidelines, and cross-functional administrative integration.

Genetic Risk Stratification

APOE Status: The presence of the Apolipoprotein E epsilon-4 (APOE e4) allele is the single most powerful risk factor for developing drug-induced ARIA.
Pathophysiology: Individuals carrying this genotype possess a substantially higher baseline vascular amyloid plaque burden (preexisting CAA). This vascular load heightens their susceptibility to rapid vessel wall breakdown, shifting, fluid leakage, and hemorrhage during anti-amyloid immunotherapy.

Routine Monitoring and Sequence Standardization

Screening Schedule: Workflows must mandate routine safety brain MRIs tightly scheduled during the first 12 months of infusions—the period of highest statistical vulnerability for developing treatment-emergent ARIA.
Baseline Synchronization: Every subsequent tracking scan must be directly and systematically co-registered to the pre-infusion baseline exam rather than relying solely on the text of interval reports. Microhemorrhages must be tracked using continuous, cumulative counting to ensure proper severity tiering over time.
Reporting Infrastructure: Departments should standardly embed structured templates (such as those provided by the ASNR Alzheimer's Disease Study Group) directly into their speech recognition software to guarantee uniform classification of mild, moderate, and severe ARIA. Acquisition parameters should align with dedicated protocols established in collaboration with major hardware vendors.
Systems Integration: Systems readiness should include deploying automatic multi-disciplinary alerts within the electronic medical record (EMR). These alerts ensure that a patient's active enrollment in an anti-amyloid program is instantly visible to outpatient care coordination coordinators, neurologists, emergency department providers, and triage staff.

Content is accurate as of the date of release